Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016 May 20. [Epub ahead of print]
   Web of Science ®Google Scholar
• Taylor CJ, Roalfe AK, Iles R, et al. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail. 2012 Feb;14(2):176–184.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21;129(3):e28–e292.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 1;63(12):1123–1133.
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Stoerk S, Filippatos G, et al. Organization of heart failure management in european society of cardiology member countries: survey of the heart failure association of the european society of cardiology in collaboration with the heart failure national societies/working groups. Eur J Heart Fail. 2013 Sep;15(9):947–959.
   PubMed Web of Science ®Google Scholar
• Kaldara E, Sanoudou D, Adamopoulos S, et al. Outpatient management of chronic heart failure. Expert Opin Pharmacother. 2015 Jan;16(1):17–41.
   PubMed Web of Science ®Google Scholar
• Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014 Sep 30;64(13):1388–1400.
   PubMed Web of Science ®Google Scholar
• Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003 Oct 1;42(7):1226–1233.
   PubMed Web of Science ®Google Scholar
• van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the european heart failure pilot survey. Eur J Heart Fail. 2014 Jan;16(1):103–111.
   PubMed Web of Science ®Google Scholar
• van Deursen VM, Damman K, van der Meer P, et al. Co-morbidities in heart failure. Heart Fail Rev. 2014 Mar;19(2):163–172.
   Google Scholar
• Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010 Jun 26;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014 Dec 2;64(21):2281–2293.
   PubMed Web of Science ®Google Scholar
• Lam CS. Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res. 2015 Jul;12(4):234–238.
   PubMed Web of Science ®Google Scholar
• Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007 Jun 26;115(25):3213–3223.
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015 Jul 14;36(27):1718,27, 1727a–1727c.
   Web of Science ®Google Scholar
• He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001 Apr 9;161(7):996–1002.
   PubMedGoogle Scholar
• Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J. 2007 Aug;154(2):277e1–277e8.
   Web of Science ®Google Scholar
• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012 Mar 13;59(11):998–1005.
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun;29(11):1377–1385.
   PubMed Web of Science ®Google Scholar
• Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The osservatorio geriatrico regione campania group. Diabetes Metab. 1997 Jun;23(3):213–218.
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med. 2003 Mar;114(4):271–275.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014 Oct;2(10):843–851.
   PubMed Web of Science ®Google Scholar
• Udell JA, Cavender MA, Bhatt DL, et al. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015 May;3(5):356–366.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):51–57.
   PubMed Web of Science ®Google Scholar
• Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005 Aug;22(8):986–993.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319–328.
   PubMed Web of Science ®Google Scholar
• Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010 Apr;31(7):824–831.
   PubMed Web of Science ®Google Scholar
• Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology foundation/American Heart Association task force on practice guidelines. Circulation. 2013 Oct 15; 128(16): e240–e327.
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. general practice research database. Diabetes Care. 2010 Jun;33(6):1213–1218.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jul 16;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Avogaro A, Degli Esposti L, et al. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the nationwide OsMed health-DB database. Eur Heart J. 2015 Sep 21;36(36):2454–2462.
   PubMed Web of Science ®Google Scholar
• Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, et al. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol. 2016 Mar 2;211:88–95.
   PubMed Web of Science ®Google Scholar
• Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016 Feb 17;352:i610.
   PubMed Web of Science ®Google Scholar
• Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Oct 5;10:CD006423.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial [Internet]; 2016 Apr 28. Available from: http://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2007805.html
   Google Scholar
• Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013 Nov;166(5):823,30.e5.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128.
   Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014 Feb;124(2):499–508.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262–274.
   PubMed Web of Science ®Google Scholar
• Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014 May;16(5):457–466.
   PubMed Web of Science ®Google Scholar
• Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016 May 14;37(19):1526–1534.
   Google Scholar
• Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015 Mar;12(2):90–100.
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [Internet]; 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm
   Google Scholar
• Summary safety review - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) - assessing the risk of the body producing high levels of acids in the blood (diabetic ketoacidosis) [Internet]; 2016. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-2-eng.php
   Google Scholar
• Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014 Jun 30;7:255–264.
   PubMedGoogle Scholar
• Nutritional anaemias. report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5–37.
   PubMedGoogle Scholar
• Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008 Sep 2;52(10):818–827.
   PubMed Web of Science ®Google Scholar
• Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006 May 23;113(20):2454–2461.
   PubMed Web of Science ®Google Scholar
• Van Veldhuisen DJ, Anker SD, Ponikowski P, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011 May 31;8(9):485–493.
   PubMed Web of Science ®Google Scholar
• Klip IT, Postmus D, Voors AA, et al. Hemoglobin levels and new-onset heart failure in the community. Am Heart J. 2015 Jan;169(1):94,101.e2.
   PubMed Web of Science ®Google Scholar
• Kleijn L, Westenbrink BD, van Deursen VM, et al. Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. Clin Res Cardiol. 2014 Jun;103(6):467–476.
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J. 2007 Jan;28(2):166–171.
   PubMed Web of Science ®Google Scholar
• van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005 Sep 20;112(12):1743–1747.
   PubMed Web of Science ®Google Scholar
• Westenbrink BD, Voors AA, de Boer RA, et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail. 2010 Jul;12(7):676–684.
   PubMed Web of Science ®Google Scholar
• Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013 Apr;165(4):575,582.e3.
   PubMed Web of Science ®Google Scholar
• Klip IT, Jankowska EA, Enjuanes C, et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur J Heart Fail. 2014 Jun;16(6):655–662.
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000 Jun;35(7):1737–1744.
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001 Jun 1;37(7):1775–1780.
   PubMed Web of Science ®Google Scholar
• van der Meer P, Voors AA, Lipsic E, et al. Erythropoietin in cardiovascular diseases. Eur Heart J. 2004 Feb;25(4):285–291.
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007 Sep;28(18):2208–2216.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007 Feb 20;49(7):753–762.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 Mar 28;368(13):1210–1219.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019–2032.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003 Sep 1;59(3):538–548.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584–590.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16;363(12):1146–1155.
   PubMed Web of Science ®Google Scholar
• Bonomini M, Del Vecchio L, Sirolli V, et al. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016 Jan;67(1):133–142.
   Google Scholar
• Finberg KE, Whittlesey RL, Fleming MD, et al. Down-regulation of bmp/smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood. 2010 May 6;115(18):3817–3826.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013 Jan 24;368(4):320–332.
   PubMed Web of Science ®Google Scholar
• Affymax and takeda announce a nationwide voluntary recall of all lots of OMONTYS® (peginesatide) injection [Internet]; 2013 [updated Feb 24, 2013. Available from: https://www.takeda.com/news/2013/20130224_5664.html
   Google Scholar
• Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 1997 Feb;51(2):553–555.
   PubMed Web of Science ®Google Scholar
• Ganz T. Systemic iron homeostasis. Physiol Rev. 2013 Oct;93(4):1721–1741.
   PubMed Web of Science ®Google Scholar
• Okonko DO, Mandal AK, Missouris CG, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011 Sep 13;58(12):1241–1251.
   PubMed Web of Science ®Google Scholar
• Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006 Dec 19;48(12):2485–2489.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015 Mar 14;36(11):657–668.
   PubMed Web of Science ®Google Scholar
• Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436–2448.
   PubMed Web of Science ®Google Scholar
• Comin-Colet J, Enjuanes C, Gonzalez G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013 Oct;15(10):1164–1172.
   PubMed Web of Science ®Google Scholar
• Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter european study. Int J Cardiol. 2014 Jun 15;174(2):268–275.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011 Nov;17(11):899–906.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Costello J, Comin-Colet J. Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. Eur J Heart Fail. 2010 Nov;12(11):1159–1162.
   PubMed Web of Science ®Google Scholar
• Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009 Jul;1790(7):682–693.
   PubMed Web of Science ®Google Scholar
• Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail. 2007 Feb;13(1):14–17.
   PubMed Web of Science ®Google Scholar
• Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013 Oct 9;168(4):3439–3442.
   PubMed Web of Science ®Google Scholar
• Niehaus ED, Malhotra R, Cocca-Spofford D, et al. Repletion of iron stores with the use of oral iron supplementation in patients with systolic heart failure. J Card Fail. 2015 Aug;21(8):694–697.
   Google Scholar
• Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011 May;26(5):1599–1607.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014 Nov;29(11):2075–2084.
   PubMed Web of Science ®Google Scholar
• Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993 Dec 8;270(22):2693–2698.
   PubMed Web of Science ®Google Scholar
• Ubbink JB, Vermaak WJ, van der Merwe A, et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr. 1993 Jan;57(1):47–53.
   PubMed Web of Science ®Google Scholar
• Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Beiser A, D’Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003 Mar 12;289(10):1251–1257.
   PubMed Web of Science ®Google Scholar
• Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004 May;147(5):924–930.
   PubMed Web of Science ®Google Scholar
• van der Wal HH, Comin-Colet J, Klip IT, et al. Vitamin B12 and folate deficiency in chronic heart failure. Heart. 2015 Feb;101(4):302–310.
   Google Scholar
• Marti-Carvajal AJ, Sola I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015 Jan 15;1:CD006612.
   PubMed Web of Science ®Google Scholar
• An JN, Lee JP, Jeon HJ, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012 Nov 21;16(6):R225.
   PubMed Web of Science ®Google Scholar
• McMahon GM, Mendu ML, Gibbons FK, et al. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012 Nov;38(11):1834–1842.
   PubMed Web of Science ®Google Scholar
• Khanagavi J, Gupta T, Aronow WS, et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014 May 12;10(2):251–257.
   PubMed Web of Science ®Google Scholar
• Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015 Sep;21(11 Suppl):S212–20.
   PubMed Web of Science ®Google Scholar
• Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009 Oct 21;302(15):1658–1665.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Anker SD, Dahlstrom U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with european society of cardiology guidelines? evidence from 12,440 patients of the ESC heart failure long-term registry. Eur J Heart Fail. 2013 Oct;15(10):1173–1184.
   PubMed Web of Science ®Google Scholar
• Poggio R, Grancelli HO, Miriuka SG. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Postgrad Med J. 2010 Mar;86(1013):136–142.
   PubMed Web of Science ®Google Scholar
• Mahoney BA, Smith WA, Lo DS, et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005 Apr;18(2):CD003235.
   Google Scholar
• Kessler C, Ng J, Valdez K, et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med. 2011 Mar;6(3):136–140.
   PubMed Web of Science ®Google Scholar
• McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (kayexalate) in sorbitol. South Med J. 2009 May;102(5):493–497.
   PubMed Web of Science ®Google Scholar
• Rafique Z, Peacock WF, LoVecchio F, et al. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia. Expert Opin Pharmacother. 2015 Aug;16(11):1727–1734.
   PubMed Web of Science ®Google Scholar
• Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014 Dec 3;312(21):2223–2233.
   PubMed Web of Science ®Google Scholar
• Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015 Jan 15;372(3):222–231.
   PubMed Web of Science ®Google Scholar
• Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404–411.
   PubMed Web of Science ®Google Scholar
• Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015 Oct;17(10):1050–1056.
   Google Scholar
• FDA approves new drug to treat hyperkalemia [Internet]; 2015 [updated Oct 22, 2015. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468546.htm
   Google Scholar
• Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820–828.
   PubMed Web of Science ®Google Scholar
• Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211–221.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015 Jul 14;314(2):151–161.
   PubMed Web of Science ®Google Scholar
• Montaperto AG, Gandhi MA, Gashlin LZ, et al. Patiromer: a clinical review. Curr Med Res Opin. 2016;32(1):155–164.
   Google Scholar
• Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct;17(10):1057–1065.
   PubMed Web of Science ®Google Scholar
• Sterns RH, Rojas M, Bernstein P, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010 May;21(5):733–735.
   PubMed Web of Science ®Google Scholar
• Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don’t: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol. 2010 Oct;5(10):1723–1726.
   PubMed Web of Science ®Google Scholar
• Batterink J, Lin J, Au-Yeung SH, et al. Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia. Can J Hosp Pharm. 2015 Jul-Aug;68(4):296–303.
   PubMedGoogle Scholar